Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
The role of carbamazepine-sensitive sodium channels in the development of type 1 diabetes
FY 2015-16
Summary
Type 1 diabetes is a condition where the body's own immune system attacks the cells in the pancreas that make the hormone insulin. When the insulin producing cells (called beta-cells) are destroyed, high blood sugar leads to a number of secondary diseases. We know that the immune system is involved, but we still do not know how the insulin producing cells are killed. So far, all efforts to treat type 1 diabetes involves 'turning down' the immune system and no available drugs protect the beta-cells directly. The Johnson lab has developed automated ways of searching for drugs that protect beta-cells from death when they are exposed to type 1 diabetes-like conditions. We have found that a drug called carbamazepine, FDA approved for epilepsy, is effective at blocking beta-cell death. Carbamazepine works by inhibiting channels that let sodium into the cells. During my undergraduate degree, I conducted a study that showed that carbamazepine dramatically reduces type 1 diabetes in mice. Now, the goal of my graduate project will be to understand exactly how this drug protects the mice from diabetes and to develop, along with our collaborators, even more effective versions of this drug. These studies are important because it will test whether sodium channels are a good target for type 1 diabetes therapy, and whether an existing drug can be re-purposed for alternative clinical use. Our ultimate goal is to find effective ways to protect insulin producing beta-cells from death in type 1 diabetes.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
350097
Name
Lee Jason T
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Prcname2
Special Cases - Awards Programs
Projecttitle
The role of carbamazepine-sensitive sodium channels in the development of type 1 diabetes
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Beta Cell; Carbamazepine; Cell Survival; Immune System; Sodium Channels; Type 1 Diabetes
Abstract
Type 1 diabetes is a condition where the body's own immune system attacks the cells in the pancreas that make the hormone insulin. When the insulin producing cells (called beta-cells) are destroyed, high blood sugar leads to a number of secondary diseases. We know that the immune system is involved, but we still do not know how the insulin producing cells are killed. So far, all efforts to treat type 1 diabetes involves 'turning down' the immune system and no available drugs protect the beta-cells directly. The Johnson lab has developed automated ways of searching for drugs that protect beta-cells from death when they are exposed to type 1 diabetes-like conditions. We have found that a drug called carbamazepine, FDA approved for epilepsy, is effective at blocking beta-cell death. Carbamazepine works by inhibiting channels that let sodium into the cells. During my undergraduate degree, I conducted a study that showed that carbamazepine dramatically reduces type 1 diabetes in mice. Now, the goal of my graduate project will be to understand exactly how this drug protects the mice from diabetes and to develop, along with our collaborators, even more effective versions of this drug. These studies are important because it will test whether sodium channels are a good target for type 1 diabetes therapy, and whether an existing drug can be re-purposed for alternative clinical use. Our ultimate goal is to find effective ways to protect insulin producing beta-cells from death in type 1 diabetes.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lee, Jason T
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~